Proportion of Treatment Programs Offering On-site Testing for HIV and STIs Decline

The proportion offering on-site testing for HIV and STIs has declined between 2000 and 2011, despite guidelines recommending opt-out HIV testing according to a new study

The proportion offering on-site testing for HIV and STIs has declined between 2000 and 2011, despite guidelines recommending opt-out HIV testing according to a new study.

"Opioid dependence is a risk factor for HIV, STIs, and hepatitis C virus (HCV) infection. Opioid treatment programs, which provide treatment to more than 300,000 opioid-dependent individuals in the United States, are well-positioned to offer testing for these infectious diseases to a high-risk population. They were among the first venues to offer HIV testing and are more likely to offer HIV, STI, and HCV testing than other drug treatment programs. Private for-profit opioid treatment programs are increasingly widespread and such programs offer on-site HIV testing less often than nonprofit and public programs. However, with the 2006 national recommendations for routine opt-out HIV testing, we hypothesized that the percentage of programs offering on-site testing for HIV, STIs, and HCV would increase," the authors write.

Life Expectancy Increases Among Treated HIV-Positive Patients
In the U.S. or Canada, a 20-year-old HIV-positive adult on antiretroviral therapy (ART) may be expected to live into their early 70's, a life expectancy approaching that of the general population.

Marcus A. Bachhuber, M.D., and Chinazo O. Cunningham, M.D., M.S., of the Albert Einstein College of Medicine, New York, analyzed data from a survey sent to directors of drug treatment facilities and tabulated the percentage of opioid treatment programs offering on-site HIV, STI, and HCV testing from 2000 to 2011.

The number of U.S. opioid treatment programs increased from 849 in 2000 to 1,175 in 2011. The percentage of programs operating as for-profit businesses increased from 43 percent to 54 percent, nonprofits decreased from 43 percent to 36 percent, and public programs decreased from 14 percent to 10 percent. From 2000 to 2011, the absolute number of programs offering testing for HIV, STIs, and HCV increased but the percentage offering on-site testing for HIV declined by 18 percent and for STIs by 13 percent. There was no change for HCV testing. More than 75 percent of public programs offered on-site testing for each infection, with no change over time.

"Declines were most pronounced in for-profit programs, suggesting that persons enrolled in these programs may be at increased risk for delayed diagnosis and continued transmission of HIV, STIs, and HCV," the authors write.

HIV-Prevention Pill Truvada Not Linked With Increased Sexual Risk Behavior
The HIV antiretroviral drug Truvada became the first and only medication approved by the FDA for HIV prevention in 2012.

"Opioid treatment programs are important venues for offering testing to high-risk individuals. As the number of for-profit opioid treatment programs increases, and the opioid, HIV, and HCV epidemics continue to intersect, further work is needed to understand and reverse declines in offering on-site testing."

Solution to HIV Puzzle may Spur Development of AIDS Drug
The chain of molecular events that drives the death of most of the immune system's CD4 T cells as an HIV infection leads to AIDS has been identified.

Source-Eurekalert